Intellia Therapeutics (NTLA) Misses Q2 EPS by 30c

Intellia Therapeutics (NASDAQ: NTLA) reported Q2 EPS of ($1.52), $0.30 worse than the analyst estimate of ($1.22). Revenue for the quarter came in at $6.96 million versus the consensus estimate of $19.68 million.

For earnings history and earnings-related data on Intellia Therapeutics (NTLA) click here.

You May Also Be Interested In

• Apple alleges defendant in trade secret case against OpenAI accessed power converter circuit schematic while at OpenAI - legal filing
• RETRANSMISSION: Gold Runner Exploration Samples Up To 25,306 Grams per Ton Silver With 11.22 Grams per Ton Gold For a Gold Equivalent of 12.7 Ounces per Ton in New 350 Meter Gold Stack Trend on the 10
• CFRA Upgrades TKO Group Holdings (TKO) to Buy